Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term phase-ii trial. Found 32 abstracts

no pagination
Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.
Ryabtsova O, Jansen K, Van Goethem S, Joossens J, Cheng JD, Lambeir AM, De Meester I, Augustyns K, Van der Veken P. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorganic & medicinal chemistry letters. 2012 May;22(10):3412-7.   PMCID: not NIH funded
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current treatment options in oncology. 2012 Sep;13(3):390-402.   PMCID: Not NIH funded
von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Aug;10(8):951-60.   PMCID: not NIH funded
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Dec;10(12):1487-98.   PMCID: Not NIH fund
Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, Meron Aj VP. Esophageal and Esophagogastric Junction Cancers. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):830-+.   PMCID: not NIH funded
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network. 2011 Apr;9(4):352-400.   PMCID: not NIH funded
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WN. Occult Primary Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2011 Dec;9(12):1358-95.   PMCID: not NIH funded
Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 2011 May;17(9):2947-54.   PMCID: not NIH funded
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical Cancer. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1388-416.   PMCID: not NIH funded
Hoffman JP. Status of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Surgical Oncology Clinics of North America. 2010 Apr;19(2):411-+.   PMCID: not NIH funded
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2010 May;117(2):324-9.   PMCID: NIH funded - needs PMCID
Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network. 2010 Nov;8(11):1228-+.   PMCID: not NIH funded
Slingluff CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8(+) and CD4(+) T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial. Clinical Cancer Research. 2009 Nov;15(22):7036-44.   PMCID: PMC 2778314
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 2005 Sep;23(9):1147-57.
Bookman MA. Is there still a role for hormonal therapy?. International Journal of Gynecological Cancer. 2005 Nov 03;15:291-7.
Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. SEMINARS IN ONCOLOGY. 2005 Jan;32(6):S23-S29.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term phase-ii trial

phase-ii trial chemotherapy NCCN Clinical Practice Guidelines NCCN Guidelines positron-emission-tomography imatinib mesylate squamous-cell carcinoma gynecologic-oncology-group growth-factor receptor metastatic colorectal-cancer gastrointestinal stromal tumors radiation therapy gist receptor kit therapy surgical-management 1st-line treatment preoperative chemoradiation sarcoma chronic lymphocytic-leukemia prognostic-factors desmoid tumor carcinoma chemoradiation surgery radiation-therapy combined-modality Response egfr gene serum thyroglobulin measurement non-hodgkins-lymphoma patients pts soft tissue laparoscopic brain metastases in-vivo cells junction cell lung-carcinoma Disease control occult primary guidelines medulloblastoma mutations tamoxifen residual disease 1995 ow wh-v274-p474 antitumor-activity needle-aspiration-cytology platinum-resistant chain-reaction assay poorly triple angiokinase inhibitor pancreatic-cancer 13 european countries oral angiogenesis inhibitor breast-cancer Network stage-iii unknown primary site soft tissue extremity sarcoma open-label Hurthle thyroidectomy radioactive papillary initial therapy gamma-knife surgery cell carcinoma papillary thyroid cancer medullary thyroid cancer randomized-trial united-states neoadjuvant chemotherapy of-the-literature intensity-modulated radiotherapy postoperative plus cetuximab high-grade dysplasia mantle-cell lymphoma pegylated liposomal zk colorectal-cancer plus chlorambucil Progression-free zk-222584 ptk ibritumomab tiuxetan radioimmunotherapy epithelial ovarian-cancer previously untreated patients brain tumor stromal lung-cancer European Society of Medical Oncology ovarian cancer esophagogastric messenger-rna bendamustine concurrent chemoradiotherapy topotecan minimally invasive esophagectomy epithelial cancers carcinoma of unknown primary tumor angiogenesis Oncology PTEN (JNCCN 2011 adenocarcinoma KIT long-term outcomes dexamethasone fibroblasts metastatic fibroblast-growth-factor Ovarian cancer high-dose advanced colorectal-carcinoma prolyl oligopeptidase cancer-research-network gastroesophageal junction primary extremity sarcoma Neoadjuvant therapy radical hysterectomy glioblastoma high-risk estrogen replacement therapy multidisciplinary care uterine cervix National Comprehensive Cancer gm-csf dendritic progression-free survival copy number alterations tyrosine kinase Multimodality therapy Esophageal carcinoma-Neoadjuvant therapy-Chemotherapy-Radiotherapy-Gastroesophageal junction (GEJ)-Esophageal cancer-Treatment system inhibitor potent amplification fibromatosis cell tissue microarray analysis radiotherapy plus concomitant NCCN Guidelines thyroid gland cancer platinum-refractory ovarian sunitinib biologic therapy receptor messenger-rna esophageal myeloid suppressor-cells cell lung-cancer Resectable pancreatic adenocarcinoma patients b-cell lymphoma
Last updated on Wednesday, July 08, 2020